The Prescription Drug User Fee Act (PDUFA) expires in September, therefore FDA may need to warn drug reviewers that their jobs may be eliminated if Congress does not honor the reauthorization deadline.
There has been considerable congressional action with regard to FDA-related legislation. The Senate recently approved the FDA Revitalization Act, setting the stage for further deliberations in the House over drug safety and FDA user fees.
The House Energy and Commerce Committee has been holding hearings on drug safety, user fees for drugs and medical devices, follow-on biologics, and food safety.
Members of the Senate Committee on Health, Education, Labor and Pensions (HELP) have promised to complete work on legislation that would allow for follow-on biologics, which could be included in a larger FDA measure during House-Senate negations on a final bill.
Although legislators and FDA are confident a user fee bill will be approved this year, final deliberations could move into the fall if issues surrounding generic drugs and drug reimportation create an impasse.
Senate HELP committee chairman Edward Kennedy (D–Massachusetts) and ranking Republican Michael Enzi (Wyoming) avoided a stalemate in the Senate by engineering compromises on a number of controversial amendments. The most prominent was an effort by Democrats to add a measure that would permit drugs to be imported from Canada. President Bush threatened to veto suchlegislation, prompting Sen Kennedy to support a second amendment that radically changes the amendment by restricting imports to drugs that FDA has deemed safe and more cost effective to Americans.
The final Senate PDUFA bill is a massive piece of legislation that includes provisions to ensure food safety and to renew medical device user fees. The bill also allows the renewal of pediatric research incentives and requirements, but reduces exclusivity to 3 months for drugs with sales of more than $1 billion.
Just before the bill moved to the Senate floor for approval, Sen Kennedy and Sen Enzi agreed to modify some of the earlier drug safety provisions, namely adding a requirement of a special risk evaluation and mitigation strategy (REMS) only for new drugs that are associated with serious adverse events during clinical trials or postapproval. The final bill also drops the 2-year waiting period for direct-to-consumer advertising of new drugs, opting instead for required presubmission of planned ads and substantial fines for marketers that run false or misleading promotions. One late change to the bill would double maximum fines to $2 million for violations of safety provisions.
The Senate also approved provisions that would curb abuses of citizen petitions to delay generic drug marketing and encourage development of new antibiotics and therapies for treatment of certain diseases.
The bill calls for FDA to manage the full life cycle of drugs, as opposed to its traditional focus on preapproval testing. The legislation includes provisions that would make it easier for FDA to mandate label changes and postapproval studies; FDA would also be required to post information regarding ongoing clinical trials and study results. The bill also allows for expansion of the electronic information systems FDA uses to evaluate adverse events and greater capacity to monitor potential safety problems associated with marketed drugs.
The final bill calls for an immediate $25 million increase in drug user fees (in addition to the $443 million in fees already expected in 2008) to support additional drug safety requirements; subsequent increases are also included in the bill.
FDA advocates say the additional funds aren't enough to meet the agency's objectives outlined in the PDUFA bill; they seek $2 billion in appropriated funds, in addition to the user fees, for 2008.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.